Chromosomes DNAread


RCT finds that previously unobserved factors contribute to oocyte aneuploidy in women aged over 35

New evaluation of the ESHRE Study into the Evaluation of oocyte Euploidy by Microarray analysis (ESTEEM) has shown that mechanisms other than abnormal chromosome segregation can cause errors during meiosis.

Assisted hatchingread


No benefit from laser-assisted hatching for subfertile couples

Fertility clinics should tell patients that there is no evidence that assisted hatching works, nor any guarantee that the add-on treatment is risk-free. This information should be provided before offering couples this adjuvant technique.


Psychosocial wellbeing

ART couples experience lower risk of anxiety and depression in pregnancy

Fear of failure, high cost, and juggling a job with clinic visits are among many factors that make fertility treatment stressful. What is unclear is whether mental distress is worse for couples who achieve a pregnancy using ART than those who conceive spontaneously.



Changing framework for infectious disease screening rules in MAR – ESHRE collaborates with the ECDC

The responsibility for setting rules on infectious disease screening in MAR will most likely move to the European Centre for Disease Prevention and Control (ECDC) following the current revision of the EU legislation on Substances of Human Origin. To support this process, the ECDC has established a new network and invited ESHRE to participate in its first in-person meeting last week.

Job lossread


Job loss linked to stillbirth and miscarriage

Data based on more than 8,000 UK pregnancies show odds of non-live birth almost double for parents-to-be who become unemployed.



Sifting through add-ons in ART: seeking clarity and the path forward

Add-ons are defined as supplementary options available to patients in addition to standard fertility procedures, with the common promise of enhancing pregnancy or live birth rates (LBRs), mitigating the risk of miscarriage, or expediting the time to achieving pregnancy (1). However, there is a lack of substantial evidence regarding the safety and efficacy of add-ons.



Exploring the embryo-maternal interface: ESHRE Campus Workshop to unveil cutting-edge research

ESHRE is thrilled to announce an exciting campus workshop, taking place in Maastricht, on the 2nd and 3rd of October. Brought to you by the Special Interest Groups Endometriosis and Endometrial Disorders, and Stem Cells, this workshop will delve into the intricate interplay between the developing embryo and maternal endometrium. We are excited to bring together a panel of prominent experts in the field who will share their latest insights and research findings.

embryo formationread


Co-treatment with an aromatase inhibitor during ovarian stimulation does not impact oocyte, embryo and pregnancy outcomes

Adding letrozole (LZ) as a co-treatment during ovarian stimulation is safe for IVF patients, according to results from a randomized controlled trial.



Fertility education and reproductive decision-making: the latest evidence to be showcased at this ESHRE Campus Workshop

The expected key message from this Campus in Lyon on 26 and 27 October is that school curricula globally should include reproductive health education.



Highlights of the global and sociocultural aspects of infertility SIG session during the IFFS 2023 conference

The European Society of Human Reproduction and Embryology (ESHRE) is steadfast in its commitment to advancing knowledge, fostering research, and promoting best practices in the field of reproductive medicine and embryology. In alignment with our objectives and in collaboration with global peers, a curated session with ESHRE’s special interest group Global and Sociocultural Aspects of Infertility, at the esteemed 2023 World Congress of the International Federation of Fertility Societies (IFFS) that was held in Athens, Greece, from 10 to 13 September 2023.

Get notified of new articles with our ESHRE newsletter.

Sign up and never miss an update